Bio-Thera signs biosimilars deal with Gedeon Richter

14 October 2024

Guangzhou, China-based Bio-Thera Solutions (688177: SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Hungary’s Gedeon Richter (RICHT: HB) have reached an exclusive commercialization and license agreement.

Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and Bio-Thera has filed BAT2206 for regulatory approval with the European Medicines Agency (EMA) on July1, 2024. For its part, Richter will have exclusive rights to commercialize the product in the European Union (EU), the UK, Switzerland and selected other countries.

Bio-Thera has previously reached a licensing and supply agreements with Pharmapark for BAT2206 with Pharmapark for exclusive rights to distribute and market the drug with a status of a local product in Russia and other Commonwealth of Independent States (CIS) countries.Bio-Thera also out-licensed this biosimilar to Hikma Pharmaceuticals (LSE: HIK) to commercialize the product in the USA.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK